Loading
Colorectal Cancer Treatments and Studies / Immune Cells in Cancer · Journal article
Cell Death and Differentiation · August 11, 2026
Encouraging direction, but not yet definitive.
This is a preclinical mechanistic study showing that EGFR deletion in myeloid cells, specifically in granulocytic MDSCs, reduces immunosuppression and sensitizes syngeneic murine CRC liver metastases to anti-PD-L1 immunotherapy. An EGFR-dependent immunosuppressive signature in MDSCs correlates with worse overall survival in pMMR CRC patients, suggesting a potentially targetable mechanism in human disease.
Syngeneic preclinical CRC liver metastasis model with genetic manipulation and mechanistic analysis. Transplanted syngeneic murine CRC model; clinical cohort consisted of pMMR CRC patients. Intervention: EGFR deletion in myeloid cells; anti-PD-L1 immune checkpoint blockade. Compared with: Wild-type or proficient myeloid EGFR; anti-PD-L1 alone or control treatment.
EGFR deletion in myeloid cells reduces metastasis development accompanied by increased intratumoural T-cell infiltration EGFR deletion reduces the capacity of granulocytic MDSCs to suppress CD4+ T-cell proliferation An EGFR-dependent signature in sorted MDSCs is associated with worse overall survival in pMMR CRC patients
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If validated in human trials, EGFR blockade in myeloid cells combined with immune checkpoint inhibitors could offer a new therapeutic strategy for RAS-mutated CRC with high EGFR+ myeloid infiltration, potentially circumventing resistance to ICB alone.
Sound preclinical mechanistic study demonstrating that EGFR deletion in myeloid cells sensitizes CRC metastases to anti-PD-L1 immunotherapy, with supporting RNA-seq data and clinical survival association, but limited by syngeneic model and lack of human trial data.
As stated by the source record.
If validated in human trials, EGFR blockade in myeloid cells combined with immune checkpoint inhibitors could offer a new therapeutic strategy for RAS-mutated CRC with high EGFR+ myeloid infiltration, potentially circumventing resistance to ICB alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Metastatic colorectal cancer (mCRC) is one of the deadliest cancers with very poor response to immune checkpoint blockade (ICB). Standard therapies employ chemotherapy combined with epidermal growth factor receptor (EGFR) blocking antibodies, which are only effective in a fraction of patients with RAS/RAF wild-type tumours. We have previously shown that EGFR deletion in myeloid cells of CRC, rather than in the cancer cells themselves, reduces tumour growth. Here, we investigate to which extent EGFR blockade in myeloid cells increases anti-tumour immunity, thus sensitising CRC to ICB. Using a syngeneic preclinical CRC liver metastasis model based on the transplantation of murine RAS mutant CRC organoids into mice lacking EGFR in myeloid cells, we observe a reduction in metastasis development accompanied by increased intratumoural T-cell infiltration. Importantly, we demonstrate that EGFR deletion reduces the capacity of granulocytic myeloid-derived suppressor cells (G-MDSCs) to suppress CD4 + T-cell proliferation. RNA-seq analysis of sorted MDSCs and T-cells uncovered an EGFR-dependent signature involved in immunosuppression, which in proficient-mismatch-repair (pMMR) CRC patients is associated with worse overall survival. Therapeutically, lifting immunosuppression by EGFR deletion in myeloid cells sensitised tumours to anti-PD-L1 treatment, thus preventing liver metastasis development. These results imply that anti-EGFR therapies combined with ICB might be successful in preventing metastasis of RAS mutated CRC with high infiltration of suppressive EGFR + myeloid cells.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.